studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 425A
Pearson chi squared tests we examined the rates of false-positive
HCC by UNOS region and transplant center. Results:
Among 3,852 transplant recipients with T2MELD exceptions
and available explant data, 262 (6.8%) had no evidence of
HCC identified on explant pathology. Rates of false-positive
HCC were higher for patients who underwent prior HCC treatment,
10.1% vs 6.5%, p = 0.014. Rates of false-positive HCC
varied by UNOS region: 2.1% false-positive rate in region 6
versus 12.0%% in region 7 (p = 0.001). There was significant
among-center variability (Figure) in false-positive rates among
those centers who transplanted ≥30 recipients with T2MELD
exceptions during the study period: ranging from 0% in four
centers to 46.0%at one center, p90%, even in patients with advanced
hepatic fibrosis. On the other hand, hepatocellular carcinoma
(HCC) develops in up to 4% of patients after successful treatment
of continuous HCV infection using interferon therapy. It is
important to evaluate hepatic pathology after HCV eradication.
The aim of the present study was to characterize microRNA
(miRNA) expression in the liver tissue of patients who achieved
an SVR. Patients and Methods: 71 tissue samples from patients
who underwent HCC resection were evaluated in the present
study: 61 HCCs from patients with continuously infected HCV
(HCV-HCC) and 10 from patients who had achieved SVR (SVR-